Home > Riviste > Minerva Pediatrica > Fascicoli precedenti > Minerva Pediatrica 2018 April;70(2) > Minerva Pediatrica 2018 April;70(2):159-64

ULTIMO FASCICOLO
 

ARTICLE TOOLS

Publication history
Estratti
Per citare questo articolo

MINERVA PEDIATRICA

Rivista di Pediatria, Neonatologia, Medicina dell’Adolescenza
e Neuropsichiatria Infantile


Indexed/Abstracted in: CAB, EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 0,764


eTOC

 

ORIGINAL ARTICLE  


Minerva Pediatrica 2018 April;70(2):159-64

DOI: 10.23736/S0026-4946.17.04280-3

Copyright © 2015 EDIZIONI MINERVA MEDICA

lingua: Inglese

Spectrum of cystic fibrosis mutations in Syrian patients

Rami A. JARJOUR , Sumaya AL-BERRAWI, Samer AMMAR, Rami MAJDALAWI

Unit of Clinical Genetics, Department of Molecular Biology and Biotechnology, Atomic Energy Commission of Syria (AECS), Damascus, Syria


PDF  


BACKGROUND: Cystic fibrosis (CF) is the most common autosomal recessive disease in Caucasians. However, it is considered to be rare in Arabs. Reports of the cystic fibrosis transmembrane regulator (CFTR) mutations from Syrians are limited. The main aim of this study was to identify the frequency of CFTR mutations in 25 CF patients. To the best of our knowledge, this is the first comprehensive report about CF in Syrian patients.
METHODS: The main clinical presentations were respiratory system symptoms (recurrent pneumonia and chronic cough) in 16 (64%) patients, failure to thrive in 15 (60%), GI system symptoms (diarrhea, steatorrhea) in 15 (60%) and nasal polyps in 1 (4%).
RESULTS: A total of 36 known mutations in the CFTR gene were screened among 25 CF Syrian patients. However, 13 different CFTR mutations were identified. These mutations in order of frequency were: ΔF508 (18%), W1282X (12%), I148T (6%), CFTRdel 2.3 (6%), 2182AA→G (6%), G542X (6%), N1303K (6%), G551D (4%), G85E (4%), R117H (4%), G85E (4%), R347P (2%), M.2183AA>G (2%) and 3199del6 (2%). However, 22% of the total mutations could not be detected in this study. Moreover, 142 healthy Syrian individuals were tested for ΔF508 and G551D mutations in an attempt to determine the carrier rate in the Syrian population. These two mutations were not detected in this cohort of healthy Syrians.
CONCLUSIONS: These results provide important tools for adapting a molecular diagnostic test and prenatal diagnosis for the Syrian population.


KEY WORDS: Cystic fibrosis - Cystic fibrosis transmembrane conductance regulator - Mutations - Syria

inizio pagina

Publication History

Issue published online: February 2, 2018
Article first published online: June 4, 2015
Manuscript accepted: May 27, 2015
Manuscript revised: April 7, 2015
Manuscript received: February 17, 2015

Per citare questo articolo

Jarjour RA, Al-Berrawi S, Ammar S, Majdalawi R. Spectrum of cystic fibrosis mutations in Syrian patients. Minerva Pediatr 2018;70:159-64. DOI: 10.23736/S0026-4946.17.04280-3

Corresponding author e-mail

ascientific@aec.org.sy